



How many patients were treated in September 2021 (or latest available month) by the dermatology department with the following drugs:

- Abrocitinib (Cibinqo) 0
- Baricitinib (Olmiant) 0
- Bimekizumab (Bimzelx) 0
- Brodalumab (Kyntheum) 1
- Dupilumab (Dupixent) 3
- Ixekizumab (Taltz) 15
- Risankizumab (Skyrizi) 4
- Guselkumab (Tremfya) 4
- Secukinumab (Cosentyx) 10
- Tildrakizumab (Ilumetri) 0
- Tralokinumab (Adtralza) 0
- Ustekinumab (Stelara) 50

Q2. How many patients were treated in September 2021 (or latest available month) by the rheumatology department with the following drugs:

- Baricitinib (Olmiant) 114
- Filgotinib (Jyseleca) 0
- Guselkumab (Tremfya) 0
- Ixekizumab (Taltz) 37
- Secukinumab (Cosentyx) 121
- Tofacitinib (Xeljanz) 94
- Upadacitinib (Rinvoq) 0
- Ustekinumab (Stelara) 2